EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:EPRSQ
CUSIPN/A
Phone617-600-3497
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$580,000.00
Price / Sales0.07
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares26,180,000
Market Cap$0.04
Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions
What is Epirus Biopharmaceuticals' stock symbol?
Epirus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."
How were Epirus Biopharmaceuticals' earnings last quarter?
Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) posted its earnings results on Tuesday, March, 15th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.07. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.41 million. View Epirus Biopharmaceuticals' Earnings History.
What is the consensus analysts' recommendation for Epirus Biopharmaceuticals?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epirus Biopharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Epirus Biopharmaceuticals' key competitors?
Who are Epirus Biopharmaceuticals' key executives?
Epirus Biopharmaceuticals' management team includes the folowing people:
- Mr. Jeff Kagy, VP of HR & Admin.
- Jason Yap, Head of Global Regulatory Affairs and Sr. Director
- Dr. Louis Boon Ph.D., Head of CLG, Bioassay & Process Devel.
- Emile Van Corven Ph.D., Head of Analytical Devel. and Downstream PD
- Dr. Mark Melville Ph.D., Sr. Director of Process Devel.
Has Epirus Biopharmaceuticals been receiving favorable news coverage?
Media headlines about EPRSQ stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Epirus Biopharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.38 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Epirus Biopharmaceuticals?
Shares of EPRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epirus Biopharmaceuticals' stock price today?
One share of EPRSQ stock can currently be purchased for approximately $0.0015.
How big of a company is Epirus Biopharmaceuticals?
Epirus Biopharmaceuticals has a market capitalization of $40,000.00 and generates $580,000.00 in revenue each year.
How can I contact Epirus Biopharmaceuticals?
Epirus Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]
MarketBeat Community Rating for Epirus Biopharmaceuticals (OTCMKTS EPRSQ)
MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EPRSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPRSQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
